PMID- 36049791
OWN - NLM
STAT- MEDLINE
DCOM- 20220908
LR  - 20221202
IS  - 1175-8716 (Electronic)
IS  - 0028-8446 (Linking)
VI  - 135
IP  - 1561
DP  - 2022 Sep 2
TI  - A service evaluation to explore Maori experiences of direct-acting antiviral 
      hepatitis C treatment in Aotearoa New Zealand.
PG  - 65-75
AB  - AIMS: Hepatitis C, and its associated life-limiting sequalae, disproportionately 
      affect Maori. Despite availability of fully funded effective and well-tolerated 
      oral direct-acting anti-viral agents (DAA), many in New Zealand remain untreated. 
      This service evaluation aimed to explore the experiences of Maori who have 
      received DAA treatment for hepatitis C, and their ideas for service improvement. 
      METHODS: This qualitative service evaluation recruited eligible participants 
      (Maori, 18 years+, DAA treatment since February 2019) through health care 
      providers. Semi-structured interviews were undertaken over the telephone with 
      consenting participants. General inductive analysis was used to generate themes 
      contextualising findings within cultural contexts for Maori, as aligned with 
      Maori methodological research practices. RESULTS: Twelve participants were 
      interviewed. The physical and mental impact hepatitis C can have, and that 
      treatment with DAA leads to improvement in these domains, were highlighted. 
      Proactivity by health professionals was valued, including the benefit of 
      wrap-around services to keep people connected throughout the treatment journey, 
      with participants articulating the ability to self-advocate when needs were not 
      met by other services. CONCLUSION: Findings can be used to enhance the 
      development of further hepatitis C treatment services, based on Maori experiences 
      of treatment and self-identified solutions for improvement in hepatitis C care.
CI  - (c) PMA.
FAU - Hikaka, Joanna
AU  - Hikaka J
AD  - Pharmacist and researcher; Planning, Funding and Outcomes; Waitemata District 
      Health Board and Auckland District Health Board, Auckland, New Zealand.
FAU - Perumal, Lavinia
AU  - Perumal L
AD  - Public health physician; Planning, Funding and Outcomes; Waitemata District 
      Health Board and Auckland District Health Board, Auckland, New Zealand.
FAU - Gauld, Natalie
AU  - Gauld N
AD  - Programme manager, School of Pharmacy, The University of Auckland, Auckland; 
      Northern Regional Alliance, Auckland, New Zealand.
FAU - Metekingi, Marara
AU  - Metekingi M
AD  - Engagement coordinator; Planning, Funding and Outcomes; Waitemata District Health 
      Board and Auckland District Health Board, Auckland, New Zealand.
FAU - Mackie, Rachel
AU  - Mackie R
AD  - General practitioner clinical lead; Planning, Funding and Outcomes; Waitemata 
      District Health Board and Auckland District Health Board, Auckland, New Zealand.
FAU - Richards, Jenny
AU  - Richards J
AD  - Programme manager; Planning, Funding and Outcomes; Waitemata District Health 
      Board and Auckland District Health Board, Auckland, New Zealand.
FAU - Bartholomew, Karen
AU  - Bartholomew K
AD  - Public health physician; Planning, Funding and Outcomes; Waitemata District 
      Health Board and Auckland District Health Board, Auckland, New Zealand.
LA  - eng
PT  - Journal Article
DEP - 20220902
PL  - New Zealand
TA  - N Z Med J
JT  - The New Zealand medical journal
JID - 0401067
RN  - 0 (Antiviral Agents)
SB  - IM
MH  - Antiviral Agents/therapeutic use
MH  - *Hepatitis C, Chronic/drug therapy
MH  - Humans
MH  - *Native Hawaiian or Other Pacific Islander
MH  - New Zealand
MH  - Qualitative Research
COIS- NG is Programme Manager for hepatitis C at the Northern Regional Alliance. All 
      authors have been involved in the "lookback and treat service" for people 
      previously diagnosed but potentially untreated Hepatitis C in the Northern 
      Region.
EDAT- 2022/09/02 06:00
MHDA- 2022/09/09 06:00
CRDT- 2022/09/01 20:42
PHST- 2022/09/01 20:42 [entrez]
PHST- 2022/09/02 06:00 [pubmed]
PHST- 2022/09/09 06:00 [medline]
PST - epublish
SO  - N Z Med J. 2022 Sep 2;135(1561):65-75.